Physician profile
Lisa Tack
NPI 1568835189
$9,902.87
in general payments reported to CMS, 2019-2025
30 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,241 · 2022: $2,325 · 2023: $1,753 · 2024: $2,327 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,229 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,228.97 |
| Education | $106.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,670.25 | 2021-2025 | |
| Pfizer INC. | $645.84 | 2021-2025 | |
| Genzyme Corporation | $571.78 | 2021-2025 | |
| Incyte Corporation | $552.82 | 2022-2025 | Opzelura |
| Almirall LLC | $538.57 | 2021-2025 | Klisyri, Seysara |
| Regeneron Healthcare Solutions, INC. | $527.29 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $517.11 | 2022-2024 | Sotyktu |
| Ucb, INC. | $435.96 | 2021-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.69 | 2022-2025 | Spevigo |
| Allergan, INC. | $359.89 | 2021-2022 | |
| Amgen INC. | $337.13 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $328.49 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $279.85 | 2021-2025 | |
| Janssen Biotech, INC. | $264.26 | 2021-2023 | Tremfya |
| Dermavant Sciences, INC. | $234.58 | 2023-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $228.67 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Lilly USA, LLC | $214.71 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $183.23 | 2021-2025 | Dysport, Aklief |
| Epi Health, LLC | $133.45 | 2021-2022 | |
| Leo Pharma INC. | $100.48 | 2022-2025 | Adbry, Anzupgo |
| Nabriva Therapeutics, Plc | $78.74 | 2022 | |
| Vyne Pharmaceuticals INC. | $75.55 | 2021 | |
| Mayne Pharma Commercial LLC | $48.95 | 2021-2023 | |
| Organon LLC | $44.36 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.78 | 2023-2025 | Jublia, Arazlo, Siliq |
| Organogenesis INC. | $32.10 | 2025 | Via Matrix |
| Biofrontera INC. | $26.44 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $19.90 | 2025 | Sofdra |
| Journey Medical Corporation | $19.39 | 2023 | |
| Revance Therapeutics, INC. | $18.61 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Tack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.